Boston Scientific Wins 14-year NIR Stent Patent Case Against J&J

Medical devices maker Boston Scientific announced that the U.S. Court of Appeals for the Federal Circuit found that its NIR Stent did not infringe Johnson &Johnson 's Fischell patent held by its subsidiary Cordis Corp.

"We are pleased with the decision and will continue to manage our litigation risks as part of our continuing effort to reduce our exposure," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.

The Judge ruled in favor of Boston Scientific in the 1998 patent infringement suit involving Johnson & Johnson. The original suit was filed in 1997.

In October 2008, the U.S. District Court Judge had awarded Johnson & Johnson damages in the amount of $406.7 million and pre-judgment interest in the amount of $296.1 million in the case involving the patent owned by Johnson & Johnson and Boston Scientific's NIR stent product. Boston Scientific said it will appeal the judgment.

The NIR stent was developed and is manufactured by Medinol, Jerusalem, Israel. Boston Scientific has an exclusive worldwide license to market and distribute the NIR stent.

The dispute was concerning to technology for balloon-expandable stents, which help doctors treat coronary heart disease.

J&J's Cordis, which specializes in the development and manufacture of interventional vascular technology, said in June that it will discontinue its clinical development program for the Nevo Sirolimus-eluting coronary stent in order to focus on other cardiovascular therapies where significant patient need exists.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
27.03.2025 • News

Moeve Joins Global Impact Coalition

The Global Impact Coalition (GIC), a collaborative platform led by CEOs and focused on achieving a net-zero chemicals future, has announced the addition of Moeve as its newest member.